Perampanel and Visuospatial Skills in Children With Epilepsy

Francesca Felicia Operto 1,*, Valentina Vivenzio 1, Chiara Scuoppo 1, Chiara Padovano 1, Michele Roccella 2, Giuseppe Quatrosi 2 and Grazia Maria Giovanna Pastorino 1

1 Child and Adolescent Neuropsychiatry Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, Italy, 2 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy

Introduction: Perampanel (PER) is a non-competitive AMPA glutamate receptor antagonist approved for focal and generalized seizures as add-on therapy. PER does not seem to negatively affect the cognitive profile in children and adolescents, but its influence on visuospatial abilities is still to be assessed. The aim of our study was to assess visuospatial skills through a standardized neuropsychological evaluation in adolescents taking PER for 12 months.

Methods: Our sample included 46 adolescents aged 12–18 years with focal and generalized drug-resistant epilepsy already in therapy with one or two antiseizure medications. Changes in visuospatial perception and memory were assessed by the Rey–Osterrieth Complex Figure Test at baseline (before taking PER) and after 12 months of pharmacological treatment. Executive functions and non-verbal intelligence were also assessed at baseline.

Results: After 12 months of PER therapy, the mean scores on the Rey–Osterrieth Complex Figure Test remained almost unchanged for both visuospatial perception and visuospatial memory skills. At baseline, visuospatial memory was related to executive function, and visuospatial perception was related to executive function and non-verbal intelligence.

Conclusions: Adjunctive treatment with PER did not negatively affect visuospatial skills. No adverse event effects have been reported after 12 months of follow-up, and this suggests a good tolerability in the middle-to-long term.

Keywords: perampanel, visuospatial memory, tolerability, adverse effects, children

INTRODUCTION

Perampanel (PER) is a relatively new antiseizure medication (ASM), approved as an additional treatment for focal-onset seizures with or without loss of awareness and primary generalized seizures in epileptic patients aged 4 years and older (1–3). Its peculiarity consists of a novel mechanism of action, different from other ASMs: PER is a selective, non-competitive antagonist to the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, an ionotropic glutamate receptor, that plays a basic part in fast excitatory synaptic transmission (4). Three phase III randomized controlled studies and subsequent open-label extension studies demonstrate the efficacy of PER as an add-on treatment of refractory focal seizures in adolescents (5–9). A subsequent multicenter, randomized, placebo-controlled study showed its efficacy in primary generalized tonic-clonic seizures in 164 patients aged 12 years and older (10).
More recently, other studies also highlighted good efficacy of PER in children from 4 years of age with different types of drug-resistant seizures (11, 12). Studies in the literature on the safety and efficacy of PER in children and adolescents have shown an overall favor risk–benefit profile with generally mild or moderate adverse effects (AEs). The most common AEs reported were dizziness (20.4%), drowsiness (15.3%), aggression (8.2%), decreased appetite (6.1%), and rhinitis (5.1%). It appears that the incidence of AEs is lower with a slower titration rate and that the AEs are reversible with the discontinuation of PER or with a dose adjustment (13).

In more recent years, tolerability research has paid increasing attention to the AEs of ASMs on cognitive function, especially in children and adolescents, whose central nervous system is still developing (14, 15). Regarding PER, the data currently available seem encouraging. A recent randomized, placebo-controlled study in adolescents with epilepsy revealed that PER had no negative effects on the global cognitive profile (16). Furthermore, executive functions, such as attention and working memory, also did not appear to be negatively affected by add-on therapy with PER in adolescent patients (17).

With the present study, we tried to fill a gap in the literature, by focusing on visual–spatial cognitive abilities and their changes during PER therapy. These abilities are important in various contexts and human actions, such as movement, non-verbal communication, spatial orientation, spatial representation, graphic production, geometric recognition, and in disparate types of problem solving and academic achievements (18, 19).

Therefore, the primary aim of our prospective observational study was to evaluate visual–spatial skills through the use of standardized tests in adolescents with focal and generalized drug-resistant epilepsy at baseline and after 12 months of add-on treatment with PER.

A secondary objective of our study was to correlate visuospatial skills with executive functions, non-verbal intelligence and some demographics and epilepsy-related characteristics (age, sex, epilepsy duration, age at onset of epilepsy, frequency of seizure, seizure type, ASM number, PER dose).

**MATERIALS AND METHODS**

**Study Design and Participants**

Our work is a prospective observational study. The patients were consecutively recruited at the Child Neuropsychiatry Unit of the University of Salerno from January 2016 to January 2020.

The eligibility criteria were as follows: focal or generalized epilepsy not well-controlled by drug therapy with one or two anticonvulsant drugs, non-verbal IQ above the fifth percentile [intelligence quotient (IQ) ≥ 70] evaluated with Raven’s progressive matrices, and normal or corrected vision. Exclusion criteria were additional neurological (cerebral palsy, neurodegenerative diseases, or migraine), psychiatric (intellectual disability, attention deficit/hyperactivity disorder, specific learning disorder, anxiety, depression, and psychosis), or other relevant medical conditions (endocrinopathies, metabolic, hepatic, cardiac, or renal disorders) that could negatively affect neuropsychological performances.

Two different epilepsy clinicians made the diagnosis using clinical observations and electroencephalogram (EEG) reports using the International League Against Epilepsy classification (20). The subtyping of focal epilepsy was made by clinical history and ictal and interictal scalp EEG characteristics.

The attending physician determined the quantity of PER for each patient to prevent side effects and control seizures.

As habitual clinical practice, all the patients underwent a standardized neuropsychological evaluation in order to assess visuospatial skills [Rey–Osterrieth Complex Figure test (RCFT)] before adding PER (baseline; n = 46) and after 12 months of drug therapy (T1; n = 42).

At the same time, executive functions and non-verbal intelligence were evaluated through EpiTrack Junior test and standard progressive matrices (SPM).

The following factors were considered in our analysis: sex, age, age at onset of seizures, duration of epilepsy, seizure frequency, seizure types, seizure outcome, and concomitant PER and ASMs dose.

All parents kept a diary of seizures and AEs. The efficacy of PER treatment was measured considering the responder rate (at least 50% reduction in seizure frequency); tolerability was evaluated considering AEs reported by parents.

All participants were informed of the study objectives and methods, and the parents signed informed consent. The study complied with the rules of good clinical practice of the Declaration of Helsinki and approved by the local Ethics Committee.

**RCFT**

RCFT is a neuropsychological assessment in which visuospatial perception and memory skills are assessed in both children and adults (21, 22).

The subjects were given a pencil and a blank sheet of paper. Subjects are initially asked to copy the figure (RCFT-Direct Copy) and after 3 min to reproduce it from memory (RCFT-Immediate Recall). There is no time limit for this test. The evaluation was based on 18 distinct elements of the figure, based on a two-point scale for a maximum of 36 points. When the graphic element is correct and positioned appropriately, two points are awarded; when the element is incomplete, incorrectly positioned, or distorted, one point is awarded; 0.5 points if incomplete and in the wrong place; 0 points when the item is missing or unrecognizable. Raw scores are converted to age-based percentile scores.

**EpiTrack Junior**

EpiTrack Junior (23) is a test used to evaluate executive functions suitable for monitoring drug treatment as it is very sensitive. It consists of six tests (visual motor speed, inhibition, visual motor planning, mental flexibility, working memory, and mental fluency) from which an age-corrected total score is obtained.

The corrected total score is 49. An executive function deficit is given by a total score below 32; in particular, a score from 31 to 29 indicates a mild deficit, and a score ≤28 points indicates
a significant deficit. A significant change in two successive measures is indicated by a loss of >2 points and a gain of >3 points.

**SPM**
The Raven Progressive Matrices is a standardized tool used to assess non-verbal intelligence in individuals ranging from age 5 to adulthood (24). There are several versions; in our study, the SPM composed of five series of 12 elements of increasing complexity were used to analyze and encode visuospatial information.

Percentiles and age-weighted standard scores (mean = 100; standard deviation = 15) were derived from the raw scores. Scores ≥5th percentile or ≥70 standard are within the normal range (25).

**Statistical Analysis**
All neuropsychological scores were reported as mean ± standard deviation (SD). The percentage of participants with a below normal score (<2 SD) was considered. The Kolmogorov–Smirnov test of normality was preliminarily performed to establish the distribution of the data. Given the presence of some data not normally distributed, non-parametric tests were used for the analyses.

Yates’ corrected chi-square test was used for the comparison of proportions. The mean score comparison was performed using the Wilcoxon signed-rank test (paired samples) or the Mann–Whitney U-test (independent sample). The comparison of the mean scores in the independent samples was made with the Kruskal–Wallis H-test.

The relationship between the different variables was evaluated with the two-tailed Spearman rank correlation test. The correlations were explained as follows: <0.2, low; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80, good; 0.81–1.00, very good.

Statistical Package for Social Science software, version 23.0 (26) was used to analyze the data. Our hypotheses were tested using Bonferroni adjusted alpha levels of 0.01 per test (0.05/5).

### RESULTS

**Sample Characteristics**
We recruited 46 adolescents aged between 12 and 18 years (mean age = 13.37 ± 1.51) affected by focal or generalized drug-resistant epilepsy, who started PER as a first or second ASM for a better seizure control. Two of them refused test administration at T1, and two were lost to follow-up.

All demographic and clinical features of the participants are summarized in Table 1; concomitant ASMs at baseline and their modification after 12 months are reported in Table 2. There were no significant differences between the main sample characteristics at baseline and T1.

Seventy percent of patients had focal seizures (with or without impaired awareness); the remaining 30% had generalized seizures. PER was added as the first add-on in 17 patients (37%) and as the second add-on in the remaining ones. Patients received a variable dose of PER ranging from 2 to 8 mg (mean dose = 3.40 ± 1.17).

| TABLE 1 | Demographic and clinical characteristics. |
|---------|------------------------------------------|
|         | T0          | T1          | Statistics T1 vs. T0 |
| N       | 46          | 42          |                         |
| Sex     |                                         |             |                         |
| Male    | 24 (52%)    | 22 (52%)    | χ² = 3.79, p = 0.861   |
| Age (years) | 13.37 (1.51) | 13.39 (1.51) | Wilcoxon             |
| Age at onset of epilepsy (years) | | |               |
| M (SD)  | 7.02 (3.50) | 7.07 (3.60) | p = 1.000             |
| Duration of epilepsy (years) | | |               |
| M (SD)  | 6.59 (4.25) | 6.60 (4.34) | p = 1.000             |
| Seizure type | | |               |
| Focal-aware | 10 (22%)    | 8 (19%)    | p = 0.961             |
| Focal-impaired awareness | 22 (48%)    | 22 (52%)    | p = 0.830             |
| Generalized | 14 (30%)    | 12 (29%)    | p = 0.966             |
| Lobe    |                                         |             |                         |
| Temporal | 23 (72%)    | 21 (70%)    | χ² = 0.31, p = 0.966   |
| Frontal | 6 (19%)     | 6 (20%)    | p = 0.843             |
| Occipital | 3 (9%)      | 3 (10%)    | p = 0.728             |
| Side    |                                         |             |                         |
| Left    | 19 (59%)    | 17 (57%)    | p = 0.966             |
| Right   | 13 (41%)    | 13 (43%)    | p = 0.966             |
| Seizure frequency (per month) | | |               |
| M (SD)  | Baseline 10.91 (6.38) | 11.00 (6.91) | p = 1.000             |
| M (SD)  | T1        | 5.52 (5.90) |                         |
| Seizure outcome | | |               |
| Seizure reduction >50% | 23 (55%) | | p = 1.000             |
| Seizure free | 6 (14%) | | p = 0.843             |
| Antiseizure drug load | | |               |
| M (SD)  | Baseline 1.63 (0.49) | 1.64 (0.48) | p = 1.000             |
| M (SD)  | T1        | 2.50 (0.68) |                         |
| PER dose (mg/d) | | |               |
| M (SD)  | 3.40 (1.17) | |                         |
| Drop-out | Cause of PER dose (mg/d) |            |                         |
| discontinue | Poor compliance | 2 | | |
| | Poor compliance | 3 | | |
| | Lost at follow-up | 4 | | |
| | Lost at follow-up | 2 | | |

M, mean; SD, standard deviation; T0, baseline; T1, 12 months follow-up; PER, perampanel.

After 12 months of PER therapy, 23 patients (55%) had ≥50% seizure reduction, and six were seizure-free (14%). No significant AEs were reported with the exception of transient irritability (n = 3) and dizziness (n = 2), which did not require drug withdrawal.

**Baseline Assessment**
On balance, analyzing the results obtained in RCFT-Direct Copy, a below normal score (<5th percentiles) was obtained by 13% (6/46) of the patients, and 15% (7/46) showed a score at the
TABLE 2 | Concomitant antiepileptic drug use at baseline and after 12 months follow-up.

| Concomitant ASM       | Baseline (N = 46) | T1 (N = 42) |
|-----------------------|------------------|-------------|
| Levetiracetam (LEV)   | 18 (39%)         | 16 (38%)    |
| Valproic acid (VPA)   | 16 (35%)         | 14 (33%)    |
| Carbamazepine (CBZ)  | 11 (24%)         | 6 (14%)     |
| Ethosuximide (ETS)    | 8 (17%)          | 4 (10%)     |
| Oxcarbazepine (OXC)   | 7 (15%)          | 5 (12%)     |
| Lamotrigine (LTG)     | 6 (13%)          | 4 (10%)     |
| Topiramate (TPM)      | 5 (11%)          | 2 (5%)      |
| Clobazam (CLB)        | 5 (11%)          | 4 (10%)     |
| Lacosamide (LCM)      | 3 (6%)           | 3 (7%)      |
| Perampanel (PER)      | 0 (0%)           | 42 (100%)   |

ASM, antiseizure medication; T1, 12 months follow-up.

TABLE 3 | Spearman correlation analysis.

| Rey-Osterrieth complex figure test (visual spatial skills) | Copy | Recall |
|-----------------------------------------------------------|------|--------|
| Epitrack Junior                                           | \( r = 0.614 \) | \( r = 0.564 \) |
| (Executive functions)                                      | \( p = 0.000^* \) | \( p = 0.000^* \) |
| SPM                                                        | \( r = 0.419 \) | \( r = 0.211 \) |
| (Non-verbal Intelligence)                                  | \( p = 0.004^* \) | \( p = 0.160 \) |
| Age                                                       | \( r = 0.215 \) | \( r = 0.112 \) |
|                                                         | \( p = 0.151 \) | \( p = 0.460 \) |
| Age at onset                                              | \( r = 0.255 \) | \( r = 0.192 \) |
|                                                         | \( p = 0.087 \) | \( p = 0.200 \) |
| Epilepsy Duration                                          | \( r = -0.236 \) | \( r = -0.213 \) |
|                                                         | \( p = 0.114 \) | \( p = 0.155 \) |
| Seizure frequency                                          | \( r = -0.051 \) | \( r = 0.142 \) |
|                                                         | \( p = 0.736 \) | \( p = 0.347 \) |
| ASM number                                                | \( r = -0.082 \) | \( r = -0.129 \) |
|                                                         | \( p = 0.589 \) | \( p = 0.392 \) |
| Perampanel dose                                            | \( r = 0.039 \) | \( r = 0.092 \) |
|                                                         | \( p = 0.797 \) | \( p = 0.542 \) |

SPM, standard progressive matrices; ASM, antiseizure medication. Asterisks (*) mark significant differences. Significant p values are in bold.

low limits of the norm (<5th–15th percentiles). The RCFT-Direct Copy mean score of the total sample at baseline was 29.09 ± 4.91.

The Spearman correlation test (Table 3) showed that RCFT-Direct Copy score was significantly related to executive functions \( r = 0.614; p < 0.001 \) and non-verbal IQ \( r = 0.419; p < 0.001 \), and there was no significant association with age, epilepsy duration, seizure frequency, age at onset of epilepsy, and ASM number (Table 2; Figure 1). There was also no significant difference in mean scores based on the following variables: sex \( r = 0.236; p < 0.001 \), and there was no significant association with age, epilepsy duration, seizure frequency, age at onset of epilepsy, and ASM number (Table 2; Figure 1).

Analyzing RCFT-Immediate Recall, we found that 24% (11/46) of patients with epilepsy showed a score under the norm (<5th percentiles), whereas 21% (8/42) showed a score at the low limits of the norm (5–15th percentiles). The RCFT-Direct Copy mean score total at baseline was 15.52 ± 5.32. The Spearman correlation test (Table 3) showed that the RCFT-Immediate Recall scores were related to executive functions \( r = 0.564; p < 0.001 \), and there was no significant association with non-verbal IQ, age, epilepsy duration, seizure frequency, age at onset of epilepsy, and ASM number (Table 2; Figure 1). There was also no significant difference in mean scores based on the following variables: sex \( r = 0.215; p < 0.001 \), and there was no significant association with age, epilepsy duration, seizure frequency, age at onset of epilepsy, and ASM number (Table 2; Figure 1).

Comparison Between T1 and Baseline

After 12 months, a below normal RCFT-Direct Copy score was obtained by 16% (7/42) of patients, and a low-limit score of normal was obtained by 19% (8/42) of patients; on the RCFT-Immediate Recall test, 20% (9/42) of patients scored below normal (<5th percentiles), and 24% (10/42) scored at the low limits of normal (5th–15th percentiles).

After 12 months, we discovered that the RCFT-Direct Copy and -Immediate Recall mean scores did not significantly differ from baseline (Table 4; Figure 2). All the results are summarized in Table 4.

DISCUSSION

With the insert of the new ASMs, which have similar effectiveness in the seizure control, a good tolerability on the cognitive profile is discriminating in the choice of the drug therapy (14). This aspect is particularly important in pediatric patients in which cognitive, executive, and visuospatial skills are indispensable for good school achievement and a good quality of life (27–29).

Our longitudinal observational study was based on 46 pediatric patients with focal or generalized drug-resistant epilepsy evaluated with neuropsychological tests for visuospatial perception and memory before and 12 months after the insert of PER as the first or second addition.

Initially, a score below normal was obtained by 13 and 24% of patients in visuospatial perception and memory, respectively, and 15 and 21% of patients scored at the lower limits of normal in these skills.

Our data confirm what has been already been described by previous research, which demonstrated a global impairment of visuospatial skills in epileptic patients compared with controls (30, 31). In general, visuospatial abilities appear to be more or less impaired even in children and adolescents with well-controlled seizures (32). Our study, in keeping with the study of Tallarita et al. (33), shows a greater impairment of
visuospatial memory rather than visuospatial perception in patients with epilepsy.

The correlation analysis in our sample showed that visuospatial perception was significantly correlated with non-verbal intelligence, and visuospatial memory was significantly correlated with both non-verbal intelligence and executive functions (e.g., attention, memory of work).

Impairment of executive functions in children and adolescents with epilepsy has already been described in previous literature studies (34). Our results suggest that visuospatial memory deficit in adolescents with epilepsy could also be linked to impairment of executive functions; however, future research should be carried out to better investigate the extent and the nature of this correlation.

In our sample, visuospatial perception and memory were not significantly related to sex, age, epilepsy duration, age at onset of epilepsy, seizure frequency, side and lobe of seizure onset, and ASM number. The data from our study are in contrast to other research, which suggests that greater impairment of cognitive function may be caused by an earlier age of onset of seizures, which affect a developing neuronal system (35, 36). The relationship between impaired visuospatial memory capacity and the side/lobe of seizure onset is controversial (37). The study by Völkl-Kernstock et al. (38) showed significant impairment in visuospatial memory in children with benign childhood epilepsy with centro-temporal spikes compared with controls, which did not depend on the side of seizure onset and drug treatment. Finally, unlike other literature studies, in our study there was no relationship between the ASM number at baseline and visuospatial functions.

However, all these aspects should be further investigated on larger samples in order to increase statistical power.

In this study, at the 12-month reassessment, the visuospatial perception and memory skills were not significantly mutated from baseline, suggesting that PER does not have a negative impact on these functions.
Generally, the ASM number is negatively associated with cognitive performance although some drugs have a better tolerability profile than others (14).

The study of Meschede et al. (39) showed that also lacosamide and PER did not determine an impairment in general cognitive abilities. The subsequent study of Meador et al. (16) shows no difference in the PER group vs. the placebo group in global cognition skills, working memory, and attention.

Our previous experience also suggests that PER had a good tolerability profile in adolescents with epilepsy, showing that, after 12 months of add-on therapy with PER, there was no worsening of executive functions and emotional–behavioral profile (17).

Concerning specifically visuospatial skills, we recently conducted an observational study on 207 pediatric patients with different types of epilepsy well-controlled by antiseizure monotherapy (40). In this study, we assessed visuospatial memory and perception at time zero (before drug therapy) and after 12 months of monotherapy with valproic acid, levetiracetam, carbamazepine, ethosuximide, or oxcarbazepine. At reassessment, subjects taking valproic acid, ethosuximide, or carbamazepine performed significantly worse in visuospatial memory, and subjects taking levetiracetam and oxcarbazepine showed no significant changes.

In this perspective, our results are in line with our previous study, according to which newer ASMs, such as PER, levetiracetam, or oxcarbazepine have a better tolerability on the cognitive profile compared to the older ASMs, such as carbamazepine, valproic acid, and ethosuximide.

In the present study, PER was effective for seizure reduction with a response rate of >50% in 23/42 subjects (55%), and 6/42 subjects were seizure-free (14%) after 12 months of therapy. No significant side effects were reported.

Other studies controlled against placebo/other ASMs and with larger sample sizes are needed to confirm our results.

CONCLUSIONS

In conclusion, PER was well-tolerated in adolescents with focal and generalized seizures. Visuospatial memory and perception were not significantly affected by PER therapy. These results, therefore, suggest that PER has a good tolerability contour in adolescence even in the medium/long term.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comitato Etico Campania Sud. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

FO conceptualized the work. GP analyzed the data and drafted the manuscript. CP, VV, and CS performed psychometric measurements and analyzed the data. GQ researched the data literature. MR supervised the work. All authors have agreed to this final version and all authors participated in a meaningful way in the preparation of the manuscript.

ACKNOWLEDGMENTS

We thank all the patients and their families who participated in the study.

REFERENCES

1. Tsai JJ, Wu T, Leung H, Desudchit T, Tiamkao S, Lim KS, et al. Perampanel, an AMPA receptor antagonist: from clinical research to practice in clinical settings. Acta Neurol Scand. (2018) 137:378–91. doi: 10.1111/an.12879
2. De Liso P, Mouvero R, Coppola G, Curatolo P, Cosmai R, De Sarro G, et al. Current role of perampanel in pediatric epilepsy. Ital J Pediatr. (2017) 43:51. doi: 10.1186/s13052-017-0368-6
3. Gil-Nagel A, Burd S, Toledo M, Sander JW, Lebedeva A, Patten A, et al. Study 504 investigator group. A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure. (2018) 54:61–6. doi: 10.1016/j.seizure.2017.10.015
4. Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. (2013) 197:19–24. doi: 10.1111/an.12100
5. French JA, Krauss GL, Biton V, Squillacote D, Yang H, Fain R, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. (2013) 54:117–25. doi: 10.1111/j.1528-1167.2012.03638.x
6. Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia. (2013) 54:126–34. doi: 10.1111/j.1528-1167.2012.03648.x
7. French JA, Krauss GL, Steinhoff BI, Squillacote D, Yang H, Kumar D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized phase III study 305. Epilepsia. (2013) 54:126–34. doi: 10.1111/j.1528-1167.2012.03648.x
8. Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia. (2013) 54:126–34. doi: 10.1111/j.1528-1167.2012.03648.x
9. Rosenfeld W, Conry J, Lagae L, Rozentals G, Yang H, Fain R, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. (2015) 19:435–45. doi: 10.1016/j.ejpn.2015.02.008
10. French JA, Krauss GL, Weblesh RT, Wang XE, DiVentura B, Brandt C, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial. Neurology. (2015) 85:950–7. doi: 10.1212/00022947-00001930
11. Renfroe JB, Mintz M, Davis R, Ferreira J, Disposto S, Ferry J, et al. Adjuvant perampanel oral suspension in pediatric patients from 2 to <12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and efficacy. J Child Neurol. (2019) 34:284–94. doi: 10.1177/0883073819827407
12. Fogarasi A, Flamini R, Milh M, Phillips S, Yoshitomi S, Patten A, et al. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures. *Epilepsia*. (2020) 61:1253–37. doi: 10.1111/epi.16413

13. Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. *Epilepsia*. (2014) 55:13–5. doi: 10.1111/epi.12504

14. Operto FF, Pasturino GMG, Mazza R, Carotenuto M, Roccella M, Marotta R, et al. Effects on executive functions of antiepileptic monotherapy in pediatric age. *Epilepsy Behav*. (2020) 102:106648. doi: 10.1016/j.yebeh.2019.106648

15. Quon RJ, Mazanec MT, Schmidt SS, Andrew AS, Roth RM, MacKenzie TA, et al. Antiepileptic drug effects on subjective and objective cognition. *Epilepsy Behav*. (2020) 104(Pt A):106906. doi: 10.1016/j.yebeh.2020.106906

16. Meador K, Yang H, Piña-Garza JE, Laurentza A, Kumar D, Wesnes K. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. *Epilepsia*. (2016) 57:243–51. doi: 10.1111/epi.13279

17. Operto FF, Pasturino GMG, Mazza R, Di Bonaventura C, Matricardi S, et al. Open-label study to investigate the safety and efficacy of adjunctive perampanel for partial-onset seizures or focal seizures or generalized tonic-clonic seizures. *Epilepsia*. (2020) 61:1253–37. doi: 10.1111/epi.16413

18. Fanari R, Meloni C, Massidda D. Visual and spatial working memory abilities predict early math skills: a longitudinal study. *Front Psychol*. (2019) 10:2460. doi: 10.3389/fpsyg.2019.02460

19. Giovagnoli G, Vicari S, Tomassetti S, Menghini D. The role of visual-spatial abilities in dyslexia: age differences in children’s reading? *Front Psychol*. (2016) 7:1997. doi: 10.3389/fpsyg.2016.01997

20. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. *Epilepsia*. (2017) 58:522–30. doi: 10.1111/epi.13670

21. Lezak MD. *Neuropsychological Assessment*. 4th Edn. New York, NY: Oxford University Press (2004).

22. Conson M, Siciliano M, Baiano C, Zappullo I, Senese VP, Santangelo G. Normative data of the Rey-Osterrieth Complex Figure for Italian-speaking elementary school children. *Neurol Sci*. (2019) 40:2045–50. doi: 10.1007/s10072-019-03929-w

23. Helmstaedter C, Schoof K, Rossmann T, Reuner G, Karlmeier A, Kurlemann G. Introduction and first validation of EpiTrack Junior, a screening tool for the assessment of cognitive side effects of antiepileptic medication on attention and executive functions in children and adolescents with epilepsy. *Epilepsy Behav*. (2010) 19:53–5. doi: 10.1016/j.yebeh.2010.06.042

24. Raven J, Raven JC. *Manual for Raven’s Progressive Matrices and Vocabulary Scales*. San Antonio, TX: Harcourt Assessment (2004).

25. Picone L, Orsini A, Pezzuti L. *Le Matrici Progressive di Raven: Contributo Alla Taratura Italiana Per Soggetti TRA i 6 e i 18 Anni*. Giunti Psychometrics S.r.l - Firenze (2018).

26. BM Corp. *IBM SPSS Statistics for Windows*, Version 23.0. Armonk, NY (2015).

27. Operto FF, Pasturino GMG, Mazza R, Roccella M, Carotenuto M, Margari L, et al. Cognitive profile in BECTS treated with levetiracetam: a 2-year follow-up. *Epilepsy Behav*. (2019) 97:187–91. doi: 10.1016/j.yebeh.2019.03.046

28. Mavero R, Santarone ME, Galasso C, Curatolo P. Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. *Brain Dev*. (2017) 39:464–9. doi: 10.1016/j.braindev.2017.01.006

29. Operto FF, Pasturino GMG, Mazza R, Di Bonaventura C, Marotta R, Pasturino N, et al. Social cognition and executive functions in children and adolescents with focal epilepsy. *Eur J Paediatr Neurol*. (2020) 28:167–75. doi: 10.1016/j.ejpn.2020.06.019

30. Cimadella JM, Lizzana JR, Roldán MD, Cánovas R, Rodríguez E. Spatial memory alterations in children with epilepsy of genetic origin or unknown cause. *Epileptic Disord*. (2014) 16:253–7. doi: 10.1684/edq.2014.0661

31. Mathon B, Bordes A, Amelot A, Carpentier A, Mérè M, Dupont S, et al. Evaluation of psychomotor functions in patients with drug-resistant epilepsy. *Epilepsy Behav*. (2020) 106:106985. doi: 10.1016/j.yebeh.2020.106985

32. Myatchin I, Laga L. Impaired spatial working memory in children with well-controlled epilepsy: an event-related potentials study. *Seizure*. (2011) 20:143–50. doi: 10.1016/j.seizure.2010.11.005

33. Tallarita GM, Parente A, Giovagnoli AR. The visuospatial pattern of temporal lobe epilepsy. *Epilepsy Behav*. (2019) 101(Pt A):106582. doi: 10.1016/j.yebeh.2019.106582

34. Reuner G, Kadish NE, Doering JH, Balke D, Schubert-Bast S. Attention and executive functions in the early course of pediatric epilepsy. *Epilepsy Behav*. (2016) 60:42–9. doi: 10.1016/j.yebeh.2016.04.011

35. Laga L. Cognitive side effects of anti-epileptic drugs. The relevance in childhood epilepsy. *Seizure*. (2006) 15:235–41. doi: 10.1016/j.seizure.2006.02.013

36. Tromp SC, Weber JW, Aldenkamp AP, Arends J, vander Linden I, Diepman L. Relative influence of epileptic seizures and of epilepsy syndrome on cognitive function. *Child Neurol*. (2003) 18:407–12. doi: 10.1177/08830738030180060501

37. Schouten D, Hendriksen JG, Aldenkamp AP. Performance of children with epilepsy on the Rey-Osterricht complex figure test: is there an effect of localization or lateralization? *Epilepsy Res*. (2009) 83:184–9. doi: 10.1016/j.eplepsies.2008.11.002

38. Volkl-Kernstock S, Willinger U, Feucht M. Spacial perception and spatial memory in children with benign childhood epilepsy with centro-temporal spikes (BCECTS). *Epilepsy Res*. (2006) 72:39–48. doi: 10.1016/j.eplepsres.2006.07.004

39. Meschede C, Witt JA, Rademacher M, von Wrede RD, Elger CE, Helmstaedter C. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. *Seizure*. (2018) 58:141–6. doi: 10.1016/j.seizure.2018.04.015

40. Operto FF, Pasturino GMG, Di Bonaventura C, Vivenzio V, Donadio S, Coppola G. Effects of antiepilepsy monotherapy on visuospatial memory in pediatric age. *Eur J Paediatr Neurol*. (2021) 32:106–14. doi: 10.1016/j.ejpn.2021.04.004

**Conflict of Interest:** FO and GP participated at advisory boards and scientific meetings for Eisai.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Operto, Vivenzio, Scuoppo, Padovano, Roccella, Quattrosi and Pasturino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.